Q3 EPS Estimate for Tarsus Pharmaceuticals Raised by Analyst

Key Points

• HC Wainwright has raised Tarsus Pharmaceuticals' Q3 2025 EPS estimate from ($0.32) to ($0.30) and maintains a "Buy" rating with a target price of $88.00.
• Despite a recent miss in Q2 earnings, reporting ($0.48) EPS against a consensus of ($0.33), Tarsus showed strong revenue of $102.66 million compared to expectations of $95.81 million.
• Insider trading is notable, with CEO Bobak R. Azamian selling 6,000 shares for a total of $332,220, representing a 0.73% decrease in his ownership.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at HC Wainwright increased their Q3 2025 earnings estimates for Tarsus Pharmaceuticals in a research report issued on Monday, October 20th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a "Buy" rating and a $88.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at $1.15 EPS, FY2027 earnings at $2.75 EPS, FY2028 earnings at $4.15 EPS and FY2029 earnings at $5.78 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The business had revenue of $102.66 million during the quarter, compared to analysts' expectations of $95.81 million.

Several other research firms have also commented on TARS. Weiss Ratings reissued a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research raised shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $69.33.

Tarsus Pharmaceuticals Trading Down 0.5%

NASDAQ TARS opened at $70.82 on Wednesday. The firm has a 50 day simple moving average of $59.54 and a 200-day simple moving average of $49.31. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. Tarsus Pharmaceuticals has a one year low of $36.07 and a one year high of $76.81. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -30.39 and a beta of 0.81.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $55.37, for a total value of $332,220.00. Following the sale, the chief executive officer owned 812,106 shares of the company's stock, valued at $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William J. Phd Link sold 27,116 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director directly owned 143,332 shares in the company, valued at approximately $8,169,924. The trade was a 15.91% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,116 shares of company stock worth $2,177,832. 8.97% of the stock is owned by corporate insiders.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amalgamated Bank raised its holdings in Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company's stock worth $66,000 after acquiring an additional 339 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company's stock worth $113,000 after acquiring an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company's stock worth $164,000 after acquiring an additional 2,782 shares during the last quarter. Finally, Quarry LP grew its position in shares of Tarsus Pharmaceuticals by 20.0% during the first quarter. Quarry LP now owns 3,599 shares of the company's stock worth $185,000 after acquiring an additional 599 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.